lyophilisation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
In April 1955, Eisenhower proposed a special economic fund for Asia. To implement Congress's August 1954 decision that technical assistance for developing countries should be put back under the State Department, Eisenhower abolished FOA in May 1955 and created the new International Cooperation Administration (ICA) in the State Department. This separated development assistance from military assistance.
=== Al–Am === Bruce Alberts (b. 1938). American biochemist at UC San Francisco, known for his work on protein complexes that enable chromosome replication in science, public policy, and as an original author of the textbook Molecular Biology of the Cell. Member Natl. Acad. Sci. USA. Robert Alberty (1921–2014). American physical biochemist at MIT, noted for many contributions to enzyme kinetics, including early studies of reactions with two substrates. Member Natl. Acad. Sci. USA. Dario Alessi (b. 1967). British biochemist at the University of Dundee known for work on protein kinases. Mary Belle Allen (1922–1973). American botanist at UC Berkeley known for demonstrating the role of chloroplasts in photosynthesis. Jorge Allende (b. 1934). Chilean biochemist at the University of Chile, known for contributions to the understanding of protein biosynthesis and how transfer RNA is generated. Member Natl. Acad. Sci. USA. C. David Allis (1951–2023), US biologist at the Rockefeller University who worked on chromatin. Richard Amasino (b. 1956). American Professor of Biochemistry and Genetics at the University of Wisconsin–Madison, who studies vernalization. Member Natl. Acad. Sci. USA. Bruce Ames (1928–2024). Biochemist and microbiologist at UC Berkeley. He is an expert on mutagenicity and an inventor of the Ames test. Awarded the National Medal of Science John E. Amoore (1939–1998). British biochemist and zoologist at UC Berkeley, who postulated the stereochemical theory of olfaction.
One barn is 10−28 square metres, about the cross-sectional area of a uranium nucleus. The name probably derives from early neutron-deflection experiments, when the uranium nucleus was described, and the phrases "big as a barn" and "hit a barn door" were used. Barn are typically used for cross sections in nuclear and particle physics. Additional units include the microbarn (or "outhouse") and the yoctobarn (or "shed").
Sources: en.wikipedia.org
While P-51s used 110-US-gallon (420 L) drop tanks over Europe, for Japan they frequently used 165-US-gallon (620 L) drop tanks which allowed more loitering time over Japan. While USAAF B-17 and B-24 bombers in Europe were arranged in combat box formations, over Japan the B-29s formed a stream that could stretch up to 200 miles. The escorting P-51s formed three Tar-Cap (Target Combat Air Patrol) squadrons, two squadrons flying on one side of the B-29 stream and the third on the other side, each squadron being 2,000 feet above and 4,000 to 5,000 feet laterally from the bomber stream. Compared to its Japanese adversaries, the P-51 largely outclassed the Imperial Japanese Army Air Service's aging A6M Zero (the most numerous Japanese fighter available), as the A6M's poor high-altitude performance put it at a disadvantage in the P-51's favorable performance envelope. When the P-51 was used for interdiction or strike missions, the A6M was slower but could still out-turn or out climb the P-51 at low to medium altitude. Newer Japanese designs were potent but too few in number. The Kawanishi N1K-J Shiden was fast and agile, but not effective as an interceptor due to a poor rate of climb and reduced engine performance at high altitude. The Imperial Japanese Army Air Service's Nakajima Ki-84 Hayate had performance and an operation ceiling that could match the P-51, however the Ki-84 suffered from manufacturing defects, and its high-maintenance Nakajima Homare engine could not reach its full potential due to lack of ample high-octane fuel.
== See also == 2026 state visit by Donald Trump to China 2026 G20 Miami summit China–United States relations List of international trips made by Xi Jinping APEC China 2026 List of international presidential trips made by Donald Trump
== Contamination and response in 2009–2010 == On 2 December 2009, China detained three employees of Shaanxi Jinqiao Dairy Company in northwest China suspected of selling 5.25 tons of melamine-laced powdered milk to Nanning Yueqian Food Additive Company, in Guangxi. On 30 December 2009, Xinhua reported continuing problems: powder and flavouring products sold by another company involved in the original scandal–the Shanghai Panda Dairy Company–were found to contain illegal levels of melamine; the dairy was closed and three of its executives arrested. On 25 January 2010, it was reported that three food companies from Hebei, Liaoning and Shandong provinces had produced melamine tainted products in March and April 2009 and that the three companies were banned from selling products in Guizhou. On 10 February 2010 China's state council announced a food safety commission, consisting of three vice premiers and a dozen minister-level officials, to address the nation's food regulatory problems. The group aims to improve government coordination and enforcement and to solve systemic food safety problems. As part of its ongoing effort to find and destroy any melamine-tainted milk remaining on the market, the Chinese government announced that it was recalling 170 tons of powdered milk laced with the industrial chemical which was supposed to have been destroyed or buried in 2008 but has recently found to have been repackaged and placed back into the marketplace.
Congenital myopathy is a very broad term for any muscle disorder present at birth. This defect primarily affects skeletal muscle fibres and causes muscular weakness and/or hypotonia. Congenital myopathies account for one of the top neuromuscular disorders in the world today, comprising approximately 6 in 100,000 live births every year. As a whole, congenital myopathies can be broadly classified as follows:
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the usual choice, with results reported as area percent. Complementary methods such as size-exclusion chromatography and mass spectrometry are needed because a single separation cannot resolve every impurity class. Purity figures are therefore method dependent and should always be read alongside the technique used.